Dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine combined with amodiaquine reduced malaria incidence by 94% and 96%, respectively, compared with a control group.
Further tests found seasonal flu, rhinovirus, COVID, and other common respiratory viruses, alongside malaria and complications from malnutrition.
The WHO says it is monitoring some JN.1-related variants, still in low proportions, that might have more immune escape than XEC.
A man from the outbreak area recently died following hemorrhagic fever symptoms, and samples have been sent to Kinshasa for testing.
After problems with earlier samples, a fuller picture of the outbreak is emerging following another round of testing.
An estimated 263 million cases and 597,000 malaria deaths occurred in 2023.
Of 12 samples, 10 were malaria-positive, but officials continue to investigate other contributing factors.
Researchers find partial resistance to artemisinin in 11 of 100 children with complicated malaria.
The report also spotlights the urgency of vaccines for pathogens such as group A Streptococcus and Klebsiella pneumoniae, which are increasingly resistant to antimicrobials.
PAHO says it will provide countries in the Americas with affordable access to respiratory syncytial virus vaccine.
